SteadMed Medical, a provider of acute and chronic wound care products, announces it has signed an agreement with PuriCore, the water-based clean technology company, to market and distribute Vashe® Wound Therapy. Vashe Wound Therapy is a safe and effective non-antibiotic alternative treatment for acute and chronic wounds that is demonstrated to be extremely gentle and hypoallergenic.
Under the terms of the multi-year agreement, SteadMed will provide marketing and distribution services for Vashe in the United States, Canada, and Mexico, and will target hospitals, wound care centers, nursing homes, and home health agencies.
Vashe Wound Therapy is an excellent addition to our portfolio of products that are specifically selected to address growing patient needs in acute and chronic wound care, said Michael Steadman, president and chief executive officer for SteadMed Medical. We believe in marketing the highest quality products available, positioned as comprehensive solutions to healthcare practitioners and to the patients they treat. Vashe Wound Therapy is a welcomed and much-needed product for the millions of patients who suffer with acute and chronic wounds.
Available by prescription only, Vashe Wound Therapy is intended for use in cleansing, irrigating, moistening and debriding acute and chronic dermal lesions, including Stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first- and second-degree burns, abrasions, and minor irritations of the skin. Vashe Wound Therapy has been rigorously safety tested and is non-cytotoxic,
non-irritating and non-sensitizing. It has no oral toxicity or clinical contraindications for use.
This agreement expands PuriCores reach through SteadMeds experienced sales, marketing, and clinical teams, while enhancing SteadMeds already strong wound care portfolio in the North American wound care market, says Michael Ashton, executive chairman of PuriCore.
Source: SteadMed Medical
